• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
Omeprazole Impurity F and G mixture

Omeprazole Impurity F and G mixture

Product ID O486188
Cas No. 125656-82-8, 125656-83-9
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $117.70 In stock
5 mg $354.60 In stock
25 mg $1,021.40 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Omeprazole Impurity F and G mixture is a mixture of the regioisomers omeprazole related compounds 8(9)-Methoxy-1,3-dimethyl-12-thioxopyrido[1’,2’:3,4]imidazo[1,2-a]benzimidazol-2-(12H) -one.

Omeprazole is a proton pump inhibitor (PPI) that acts as an antagonist at H+/K+ ATPases and is clinically used to treat gastroesophageal reflux disease (GERD), dyspepsia, and peptic ulcer disease. Omeprazole exhibits antacid, anti-ulcerative, and anti-diabetic activities; it also inhibits the mitochondrial carnitine/acylcarnitine transporter. Omeprazole decreases blood glucose levels and Hb1Ac, improves glucose tolerance, and induces β cell neogenesis and activation.

Product Info

Cas No.

125656-82-8, 125656-83-9

Purity

≥98%

Formula

C16H13N3O2S

Formula Wt.

311.4

Chemical Name

8-methoxy-1,3-dimethyl-12-thioxobenzo[4',5']imidazo[2',1':2,3]imidazo[1,5-a]pyridin-2(12H)-one compound with 9-methoxy-1,3-dimethyl-12-thioxobenzo[4',5']imidazo[2',1':2,3]imidazo[1,5-a]pyridin-2(12H)-one (1:1)

Synonym

Omeprazole Related Compound F and G mixture; Omeprazole EP Impurity F and G mixture.

Solubility

Soluble in ethanol or methanol. Slightly soluble in acetone, isopropanol, or water.

Shipping and Storage

Store Temp

-80°C

Ship Temp

Ambient

Downloads

Info Sheet

O486188 Info Sheet PDF

References

Tonazzi A, Eberini I, Indiveri C. Molecular mechanism of inhibition of the mitochondrial carnitine/acylcarnitine transporter by omeprazole revealed by proteoliposome assay, mutagenesis and bioinformatics. PLoS One. 2013 Dec 9;8(12):e82286. PMID: 24349247.

Ward RM, Kearns GL. Proton pump inhibitors in pediatrics : mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics. Paediatr Drugs. 2013 Apr;15(2):119-31. PMID: 23512128.

Mefford IN, Mefford JT, Burris CA. Improved diabetes control and pancreatic function in a type 2 diabetic after omeprazole administration. Case Rep Endocrinol. 2012;2012:468609. PMID: 22937295.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • S8044

    R,S-Sulforaphane, High Purity

    Phase II enzyme inducer; Nrf2 activator; antiox...

    ≥99%
  • B1855

    O6-Benzylguanine

    MGMT inhibitor.

    ≥98%
  • K4401

    KL-1 Peptide

    Peptide, c-Kit ligand fragment.

    ≥95%
  • N1721

    Nefiracetam

    Pyrrolidone; NMDA and mGluR5 agonist, N-type an...

    ≥98%
  • I5354

    Iniparib

    Cysteine adduct inducer, PARP-1 inhibitor.

    ≥98%
  • T0115

    Taxol Side Chain Acid

    Side chain commonly attached to taxanes.

    ≥98%
  • D5692

    Doxifluridine

    5-Fluorouracil prodrug, pyrimidine nucleoside a...

    ≥98%
  • C3210

    Ciglitazone

    Thiazolidinedione; PPARγ agonist.

    ≥98%
  • M1779

    Methyldopa Sesquihydrate

    DOPA decarboxylase inhibitor, indirect α2-adre...

    ≥98%
  • P4782

    PluriSIn 1

    Stearoyl-coA desaturase 1 inhibitor.

    ≥98%
  • D0182

    Daunorubicin Hydrochloride

    Anthracycline, DNA intercalator; topoisomerase ...

    ≥98%
  • M184774

    5-(Methylsulfinyl)pentyl Nitrile

    Synthetic compound related to sulforaphane.

    ≥98%
  • H014458

    Halometasone

    Glucocorticoid

    ≥98%
  • R5772

    Rosiglitazone Maleate

    Thiazolidinedione; PPARγ agonist.

    ≥98%
  • T1010

    7-Acetyl Paclitaxel

    Synthesis impurity

    ≥98%
  • B6959

    Bromosporine

    BRD2/4/9 and CECR2 inhibitor.

    ≥99%
  • R3224

    Rigin

    Peptide, IgG derivative, tuftsin analog.

    ≥95%
  • A0002

    A66

    p110α PI3K inhibitor.

    ≥98%
  • I7447

    1-Isothiocyanato-6-(methylsulfenyl)-hexane

    Synthetic ITC, erucin analog.

    ≥98%
  • E5217

    β-Endorphin, human

    Endogenous opioid peptide; μOR agonist.

    ≥95%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only